Form 4: Ligand Pharmaceuticals Director Jason Aryeh Reports Acquisition of Restricted Stock Units and Stock Options

Director Jason Aryeh reports acquisition of restricted stock units and stock options in Ligand Pharmaceuticals.

Summary

• On June 14, 2024, Jason Aryeh, a director of Ligand Pharmaceuticals, acquired 1,252 restricted stock units (RSUs) and 5,444 non-qualified stock options.
• The RSUs were granted by the Board of Directors at their annual meeting and vest fully on the earlier of the next annual meeting or the first anniversary of the grant date.
• The stock options, also granted at the annual meeting, have an exercise price of $80.06 and expire on June 14, 2034.
• Following the reported transactions, Mr. Aryeh directly owns 78,080 shares of common stock and indirectly owns 51,594 shares through JALAA Equities, LP, JLV Investments, LP and affiliates, and 5,025 shares by Trust.
• He also directly owns 5,444 derivative securities (non-qualified stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock transactions. The acquisition of stock options and RSUs by a director can be seen as a mildly positive sign, indicating confidence in the company's future.

Positives

• The acquisition of RSUs and stock options by a director signals confidence in the company's future performance.
• The vesting schedule of the RSUs and stock options incentivizes long-term commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the RSUs and stock options suggests an expectation of continued service and contribution from the director.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to align management's interests with those of shareholders.
• The vesting schedules for RSUs and stock options are generally consistent with industry norms, typically ranging from one to four years.

Stakeholder Impact

• The reported transactions provide transparency to shareholders regarding insider ownership.
• The vesting schedule of the RSUs and stock options may incentivize the director to contribute to the company's long-term success.

Key Dates